TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.
- Institutional Review Board approval obtained for veteran mental health trial
- 15 participants enrolled to date with trial completion expected this quarter
- Pilot agreement signed with MLB-affiliated academy to monitor athlete wellness
- Single-channel ECG algorithm used to screen for major depressive episodes and sleep quality
- Cash balance reported at $1.24 million with ongoing R&D investment
Clinical Trial Milestone in Veteran Mental Health
TrivarX Limited (ASX – TRI) has marked significant progress in its clinical development strategy by securing Institutional Review Board approval for a trial aimed at screening major depressive episodes in US military veterans. The trial, conducted in partnership with the United States Department of Veterans Affairs (VA) and the Greater Los Angeles Veterans Research and Education Foundation (GLAVREF), leverages TrivarX's proprietary single-channel ECG algorithm. This technology uses heart rate and heart rate variability metrics to assess sleep stages and detect current major depressive episodes (cMDE), potentially offering a more objective and accessible screening tool.
Recruitment is underway at the West Los Angeles VA Medical Center, with 15 participants enrolled so far out of a targeted 30. The trial compares the algorithm's performance against gold-standard clinical assessments, including polysomnography for sleep and the Mini International Neuropsychiatric Interview for depression diagnosis. Completion is anticipated within the current quarter, positioning TrivarX to validate its technology in a critical healthcare segment.
Expanding Into Professional Sports with Wearable Tech
In a strategic move into the competitive sports technology arena, TrivarX has initiated a pilot program with a Major League Baseball-affiliated academy in the Dominican Republic. This pilot will deploy wearable devices embedded with the company's single-lead ECG algorithm to monitor sleep and mental wellness among approximately 40 athletes over two weeks. The goal is to quantitatively measure factors that could predict and prevent performance slumps, a novel application of mental health technology in elite sports.
The Dominican Republic, home to 30 MLB academies, represents a fertile testing ground given its rich baseball heritage and the government's support, notably from Baseball Commissioner Junior Noboa. This initiative not only diversifies TrivarX's commercial prospects but also underscores the growing intersection between mental health monitoring and athletic performance optimization.
Scientific Recognition and Financial Position
TrivarX further bolstered its scientific credentials by presenting two research posters at Sleep 2025, the premier US congress on sleep medicine. These presentations highlighted the company’s advances in ECG-based machine learning for depression screening and its potential as a screening alternative in complex sleep disorder patients.
Financially, TrivarX reported a cash balance of $1.24 million at quarter-end, reflecting ongoing investment in research and development. Operating and investing activities consumed $0.23 million and $0.67 million respectively during the quarter. While the company maintains a runway of just over five quarters at current burn rates, continued progress in clinical validation and commercial partnerships will be critical to sustaining momentum.
Looking Ahead
Non-executive Chairman David Trimboli emphasized the company’s exceptional progress and the promising entry into professional sports technology. The coming weeks will focus on completing the veteran trial and exploring expansion opportunities for the MLB pilot program. These developments position TrivarX at the forefront of integrating objective physiological data into mental health and performance monitoring.
Bottom Line?
TrivarX’s dual-track approach in veterans’ mental health and elite sports could unlock new commercial frontiers, but upcoming trial results and financial sustainability remain key watchpoints.
Questions in the middle?
- Will the veteran trial confirm the algorithm’s accuracy and lead to broader clinical adoption?
- How scalable is the MLB wearable pilot, and can it attract further sports partnerships?
- What funding strategies will TrivarX pursue to extend its cash runway beyond five quarters?